Value of FLT-PET Before and During Radiotherapy in Head and Neck Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00163176|
Recruitment Status : Completed
First Posted : September 13, 2005
Last Update Posted : December 16, 2011
Tumor cell proliferation and repopulation contribute to resistance to radiotherapy in head and neck cancer. Up to now, this characteristic is mostly assessed using biopsies acquired during inspection under general anaesthesia before treatment.
18F-FLT-PET (positron emission tomography) is a non-invasive imaging method showing areas of active proliferation. The aim of this study is to assess the value of the functional information gained by 18F-FLT-PET for radiotherapy planning and early tumor response assessment.
Prior to radiotherapy, a planning CT-scan and a 18F-FLT-PET scan are acquired. After approximately two weeks of radiotherapy a further PET scan is obtained.
|Condition or disease|
|Head and Neck Neoplasms|
|Study Type :||Observational|
|Actual Enrollment :||50 participants|
|Official Title:||Value of FLT-PET Before and During Radiotherapy in Head and Neck Tumors|
|Study Start Date :||July 2005|
|Actual Primary Completion Date :||December 2008|
|Actual Study Completion Date :||December 2010|
- Correlation of 18F-FLT-PET-signal changes before and during therapy with treatment outcome (clinical response and local tumor control) [ Time Frame: 1 year ]
- Evaluation of the value of the functional information gained by 18F-FLT-PET regarding the definition of the planning target volume (PTV) for radiotherapy. [ Time Frame: 2 months ]
- Measurement of 18F-FLT-PET-signal changes during radiotherapy or radiochemotherapy. [ Time Frame: 2 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00163176
|Radboud University Nijmegen, Department of Radiotherapy|
|Nijmegen, Gelderland, Netherlands, 6500 HB|
|Principal Investigator:||Johannes HA Kaanders, PhD||Radboud University|